Julie Hortelano

Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination

P. Erbs, K. Rittner, Fiorella Kotsias, 2022, Clinical & translational immunology.

Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.

K. Rittner, A. Carpentier, C. Jakobs, 2017, Vaccine.

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1

J. Marchand, J. Foloppe, P. Erbs, 2019, Journal of Virology.

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

K. Rittner, C. Thioudellet, X. Préville, 2017, Human vaccines & immunotherapeutics.

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer

J. Foloppe, P. Erbs, H. Huet, 2020, Molecular therapy oncolytics.

Yeast Virus-Derived Stimulator of the Innate Immune System Augments the Efficacy of Virus Vector-Based Immunotherapy

G. Hartmann, P. Romby, J. Marchand, 2014, Journal of Virology.